BACKGROUND: Approximately 190,000 Americans are diagnosed with @entity1149 ( @entity1149 ) annually, and about half have metastatic (Stage IV) disease. These @entity1 have historically had poor survival prognosis, but several new therapies introduced since 2000 provide options for improved outcomes. The objectives of this study were to quantify survival gains from 1990, when best supportive care (BSC) only was standard, to 2015 and to estimate the impact of expanded use of systemic therapies in clinically appropriate @entity1 . MATERIALS AND METHODS: We developed a simulation model to estimate survival gains for @entity1 with metastatic @entity1149 from 1990-2015. Survival estimates were derived from major clinical trials and extrapolated to a lifetime horizon. Proportions of @entity1 receiving available therapies were derived from the Surveillance, Epidemiology, and End Results database and a commercial treatment registry. We also estimated gains in @entity1349 ( @entity1349 ) in scenarios in which systemic therapy use increased by 10% and 30% relative to current use. RESULTS: From 1990-2015, one-year survival proportion increased by 14.1% and mean per- @entity1 survival improved by 4.2 months (32,700 population life years). Increasing treated @entity1 by 10% or 30% increased @entity1349 by 5.1 months (39,700 population life years) and 6.9 months (53,800 population life years), respectively. CONCLUSION: Although survival remains poor in metastatic @entity1149 relative to other common @entity5 , meaningful progress in per- @entity1 and population-level outcomes has been realized over the past 25 years. These advances can be improved even further by increasing use of systemic therapies in the substantial proportion of @entity1 who are suitable for treatment yet who currently receive BSC only. The Oncologist 2017;22:1-7Implications for Practice: Approximately 93,500 Americans are diagnosed with metastatic @entity1149 ( @entity1149 ) annually. Historically, these @entity1 have had poor survival prognosis, but newer therapies provide options for improved outcomes. This simulation modeling study quantified metastatic @entity1149 survival gains from 1990-2015. Over this period, the one-year survival proportion and mean per- @entity1 survival increased by 14.1% and 4.2 months, respectively. Though metastatic @entity1149 survival remains poor, the past 25 years have brought meaningful gains. @entity1017 could be realized by increasing systemic therapy use in the substantial proportion of @entity1 who are suitable for treatment, yet currently receive only supportive care.

Survival Gains from First-Line Systemic Therapy in Metastatic XXXX in the U.S., 1990-2015: Progress and Opportunities.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['Additional gains'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1149 :: (MESH:D002289,Disease) :: ['Non-Small Cell Lung Cancer']
